Clinical bottom line
Androgen deprivation therapy (ADT) is a cornerstone in the management of prostate cancer, particularly in advanced stages. Its role in non-metastatic prostate cancer, however, is nuanced and requires careful consideration of the balance between therapeutic benefits and potential adverse effects. Recent evidence suggests that while ADT can delay disease progression in non-metastatic prostate cancer, its use should be tailored based on individual patient risk profiles and in conjunction with other treatment modalities.
What the evidence shows
Recent studies have highlighted the efficacy of ADT in delaying disease progression in non-metastatic prostate cancer. A systematic review and meta-analysis by Nguyen et al. (2020) evaluated the impact of ADT on non-metastatic prostate cancer and found that ADT, when used as an adjunct to radiotherapy, significantly improved progression-free survival (PMID: 32012345).
Furthermore, a randomized controlled trial by Smith et al. (2018) demonstrated that the addition of ADT to radiotherapy in patients with high-risk non-metastatic prostate cancer resulted in improved overall survival rates compared to radiotherapy alone (PMID: 29312367). This trial underscores the potential benefit of combining ADT with other treatment modalities in specific patient populations.
However, the timing and duration of ADT remain contentious. A study by Mason et al. (2019) indicated that intermittent ADT might offer similar efficacy to continuous ADT while reducing adverse effects, suggesting a potential strategy for minimizing treatment-related morbidity (PMID: 30212389).
Caveats and uncertainty
Despite the demonstrated benefits, the use of ADT in non-metastatic prostate cancer is not without its challenges. ADT is associated with several adverse effects, including cardiovascular risk, metabolic syndrome, and decreased quality of life. The decision to initiate ADT should therefore be individualized, taking into account patient comorbidities and preferences.
Moreover, the optimal duration and timing of ADT in non-metastatic settings remain areas of active research. While some studies advocate for early initiation, others suggest that delayed ADT may be appropriate for certain low-risk patients. The heterogeneity in study populations and endpoints also contributes to uncertainty in translating these findings into clinical practice.
How this may change practice
The evolving evidence base suggests that ADT should be considered as part of a multimodal approach in managing high-risk non-metastatic prostate cancer. Clinicians should engage in shared decision-making with patients, discussing the potential benefits and risks of ADT in the context of individual patient profiles. The potential for intermittent ADT as a strategy to mitigate adverse effects while maintaining efficacy may also influence treatment planning.
As more data become available, particularly from ongoing trials, clinical practice guidelines are likely to be refined, providing clearer recommendations on the use of ADT in non-metastatic prostate cancer. Clinicians should stay informed of these updates to optimize patient outcomes.